This compound, known as GS-9256, is a potent and selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is primarily utilized in medicinal chemistry and antiviral drug development for the treatment of chronic HCV infection. By targeting the viral protease, it disrupts the cleavage of the HCV polyprotein, thereby inhibiting viral replication and reducing viral load. Researchers employ it in preclinical and early clinical studies to assess its efficacy, particularly in combination therapies with other direct-acting antivirals, as well as its safety, pharmacokinetics, and potential for resistance development. This compound contributes to advancements in HCV therapeutics, aiding in the pursuit of curative regimens for this global health concern.